Recently, the Finotonlimab Injection (trade name: 安佑平/Anyouping) of Sino Cell Technologies Inc. is approved for marketing by China NMPA. Indications: This product is indicated for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck in combination with platinum-containing chemotherapy.

Finotonlimab Injection is a recombinant humanized anti-programmed death receptor-1 (PD-1) monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby inhibiting tumor growth. The marketing of this drug provides a new treatment option for relevant patients.